ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH EVAN YU
Management of mCRPC using Sipuleucel-T

VIEW ALL mCRPC VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH JACOB BERCHUCK & MARY-ELLEN TAPLIN
Genetic Risk in Prostate Cancer

VIEW ALL PROSTATE CANCER VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH KARIM FIZAZI
ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life

VIEW ALL nmCRPC VIDEOS

EAU 2019 ANNUAL MEETING

EAU 2019 ANNUAL MEETING

INTERVIEW WITH THOMAS POWLES
Immunotherapy in the Peri-Operative Setting for Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

EAU 2014 - Assessing the optimal postoperative management of node positive prostate cancer patients: Results from a large, multi-institutional series - Session Highlights

STOCKHOLM, SWEDEN (UroToday.com) - The optimal management of lymph node positive prostate cancer (PC) remains controversial. Current data support the use of adjuvant androgen deprivation therapy (ADT) following radical prostatectomy (RP) for patients with node positive disease. The benefit of adjuvant hormonal therapy among men with micrometastatic node positive disease is limited. Dr. N. M. Passoni presented his group's analysis of a large, multi-institutional, retrospective cohort. A total of 1 338 patients undergoing RP between 1988 and 2010 with N+ disease from 3 institutions were reviewed. Patients were stratified into observation (27.9%), adjuvant ADT (48.7%), or a combination of ADT and adjuvant radiotherapy (RT) (23.4%).

eauAt a median follow-up of 72 months (range 49-128 months), 7-year cancer specific and overall survival rates were 84.7%, 88.4%, 93.8% and 82.8%, 79.4% and 90.0% for patients undergoing observation, ADT, and combination radiotherapy/ADT, respectively. Following multivariable adjustment for age, pathological Gleason score and stage at surgery, number of positive lymph nodes, and surgical margin status, combination ADT + adjuvant RT (HR 0.26) and ADT alone (0.64) were associated with a significant decreased risk of cancer specific mortality. Not unexpectedly, Gleason score 8 or greater disease, pT3b or T4 disease, positive surgical margins, and ≥ 3 positive lymph nodes were associated with increased risk of cancer specific mortality. Further, use of ADT alone increased the risk of overall mortality (HR 3.0), while combination RT and ADT did not.

In conclusion, treatment with combination adjuvant RT and ADT was associated with improved cancer-specific mortality compared to observation or ADT alone following RP for patients with lymph node positive disease. However, given the retrospective nature of this analysis, despite multivariable adjustment, the results likely reflect selection bias. Patients selected for ADT and adjuvant RT may have been healthier and/or were perceived more likely to benefit from combination therapy. Further prospective studies are needed to provide definitive answers.

Presented by N. M. Passoni at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

Urological Research Institute, University Vita-Salute San Raffaele, Dept. of Urology, Milan, Italy

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe